Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting.
about
Medical treatment for gastro-entero-pancreatic neuroendocrine tumoursAdvancement in treatment and diagnosis of pancreatic cancer with radiopharmaceuticalsPancreatic insulinomas: Laparoscopic managementFrom targets to treatments: a review of molecular targets in pancreatic neuroendocrine tumorsPI3K-AKT-mTOR-signaling and beyond: the complex network in gastroenteropancreatic neuroendocrine neoplasmsPET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literatureClinical utility of lanreotide Autogel® in gastroenteropancreatic neuroendocrine tumorsThe imaging of insulinomas using a radionuclide-labelled molecule of the GLP-1 analogue liraglutide: a new application of liraglutideSomatostatin receptor expression on von Hippel-Lindau-associated hemangioblastomas offers novel therapeutic target.Selection of radiolabeled gastrin analogs for peptide receptor-targeted radionuclide therapy.Peptide-based probes for targeted molecular imaging.Cancer biology in diabetes.Preclinical evaluation of PAC1 targeting with radiolabeled Maxadilan.Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives.68Ga-labelled exendin-3, a new agent for the detection of insulinomas with PET.Molecular imaging with ⁶⁸Ga-SSTR PET/CT and correlation to immunohistochemistry of somatostatin receptors in neuroendocrine tumours.CCK(2) receptor splice variant with intron 4 retention in human gastrointestinal and lung tumours.Comparing of IRS and Her2 as immunohistochemical scoring schemes in gastroenteropancreatic neuroendocrine tumorsMolecular imaging of Cathepsin E-positive tumors in mice using a novel protease-activatable fluorescent probe.Expert consensus for the management of advanced or metastatic pancreatic neuroendocrine and carcinoid tumors.Radiolabelled GLP-1 analogues for in vivo targeting of insulinomas.Positron emission tomography imaging of cancer biology: current status and future prospectsThe identification of gut neuroendocrine tumor disease by multiple synchronous transcript analysis in bloodA new 18F-labeled BBN-RGD peptide heterodimer with a symmetric linker for prostate cancer imaging.Preclinical evaluation of 68Ga-DOTA-minigastrin for the detection of cholecystokinin-2/gastrin receptor-positive tumors.Distribution of cholecystokinin-B receptor genotype between patients with pancreatic cancer and controls and its impact on survival.Applications of molecular imaging.Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 1--molecular pathways.PET of insulinoma using ¹⁸F-FBEM-EM3106B, a new GLP-1 analogueDesign and synthesis of a bombesin peptide-conjugated tripodal phosphino dithioether ligand topology for the stabilization of the fac-[M(CO)3]+ core (M=(99 m)Tc or Re)The effect of co-administration of Lawsonia inermis extract and octreotide on experimental hepatocellular carcinomaSynthesis and evaluation of [18F]exendin (9-39) as a potential biomarker to measure pancreatic β-cell mass.A limiting factor for the progress of radionuclide-based cancer diagnostics and therapy--availability of suitable radionuclides.Receptor-mediated tumor targeting with radiopeptides. Part 1. General concepts and methods: applications to somatostatin receptor-expressing tumors.99mTc Labeled Glucagon-Like Peptide-1-Analogue (99mTc-GLP1) Scintigraphy in the Management of Patients with Occult Insulinoma.Evaluation of an [(18)F]AlF-NOTA Analog of Exendin-4 for Imaging of GLP-1 Receptor in InsulinomaMifepristone Improves Octreotide Efficacy in Resistant Ectopic Cushing's Syndrome.[(177)Lu-DOTA](0)-D-Phe(1)-Tyr(3)-Octreotide ((177)Lu-DOTATOC) For Peptide Receptor Radiotherapy in Patients with Advanced Neuroendocrine Tumours: A Phase-II Study.68Ga-NOTA-Exendin-4 PET/CT in Localization of an Occult Insulinoma and Appearance of Coexisting Esophageal Carcinoma.Glucagon-like peptide-1 receptor imaging with [Lys40(Ahx-HYNIC- 99mTc/EDDA)NH2]-exendin-4 for the detection of insulinoma.
P2860
Q26751659-F7953255-3751-4BA7-874A-323FF897B893Q26766690-5EB63202-038D-41D6-B0C6-E35635B136D1Q26777226-D9927697-7517-4FD9-BF9A-4295F92D59B4Q26822011-5083B63D-78D4-4B76-8AD6-FFF4CFA9BF9CQ26862544-DBF9CD98-93B6-4782-8C49-F6B10CDE3489Q26992201-5C424F1E-10BF-4602-8802-B76A32CDE5B5Q28069632-4C580A12-E18D-40BA-929B-B93820E6DE7EQ28538567-E1A26F4E-69D7-41FA-9160-64FE7039EF74Q30274979-F3188756-426C-43DE-B34D-DEA38FA59AFAQ33280762-FD6984FA-7FE8-4CE3-91F0-48894905B038Q33526620-6E83114A-D051-400D-946E-C988D01C46BAQ33608038-67C33A51-5404-498F-84F3-0E09DB167D35Q33687453-9526FA20-989B-4C6C-9532-18719EA906E7Q33753449-1A3EDAE2-CBC0-49FD-9C6F-1C7707051A56Q33915233-8A8C1215-3C2F-4A9E-B474-1B52E6FCEAB4Q33917064-0A9F88FA-2C54-469B-9930-0294A403F2AEQ33925682-AB6FBE55-E03E-42A5-BD25-17566A181CA5Q34257556-E71F0C57-B33A-4E36-BFB0-D63EC17A837FQ34392691-1A5E40CA-88D6-452F-BD15-5B67E8E4AF2FQ34452319-176D7E54-3AB0-4570-897D-A3FF14E973A5Q34579936-6299C28A-AB4A-4546-AB86-C430C54E4AF3Q34697688-904BFB2F-C8D8-43DD-84E4-72CF6D1050B3Q34730350-72697B66-6C39-447D-81BA-BA3A8E419D6CQ35009658-57ACBE5B-6D46-4144-865C-6D089B792C48Q35069148-28319349-F4C2-4651-97F4-012F612D66C3Q35079421-1262D1F1-3BFB-45CF-A642-E808938E40CCQ35082412-3D622C5B-F60B-4830-8506-9B5D58CD193DQ35216414-4A27F43B-B190-4410-AB3E-9119CF6E745BQ35256800-B41FF691-A4FE-4EF4-BFB7-DBA6C5A2D093Q35609666-E07E189B-616F-4940-8267-8DC758833ED0Q35614440-2901C245-84BD-467C-8087-1C7A080BA2B3Q35794797-F9A8783D-35F4-4F58-9C10-26837C3C0EFAQ35831439-71863491-F782-42B8-BE72-FE7E8F1B4EBDQ36008285-86BF9D2A-119A-4626-AEF4-4B9C2B8B05D4Q36104200-2421B164-C0CD-4A90-A1EE-4EF79806297EQ36383709-8DD513CD-8080-414B-B2AB-D4F8A1F397F8Q36637525-C490F2BD-7606-45F8-BCFB-CC8C7C579747Q36644325-3946425C-082C-4086-9B2F-23DD8288F664Q36655954-AA76779F-D9A0-4787-8042-09BCC6823672Q36662850-4411DEA7-C1B9-41A6-8FB3-3009A2FFFDED
P2860
Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting.
description
2003 nî lūn-bûn
@nan
2003 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Concomitant expression of seve ...... ultireceptor tumour targeting.
@ast
Concomitant expression of seve ...... ultireceptor tumour targeting.
@en
type
label
Concomitant expression of seve ...... ultireceptor tumour targeting.
@ast
Concomitant expression of seve ...... ultireceptor tumour targeting.
@en
prefLabel
Concomitant expression of seve ...... ultireceptor tumour targeting.
@ast
Concomitant expression of seve ...... ultireceptor tumour targeting.
@en
P1476
Concomitant expression of seve ...... ultireceptor tumour targeting.
@en
P2093
Beatrice Waser
P2888
P304
P356
10.1007/S00259-003-1184-3
P577
2003-04-18T00:00:00Z